

Review Article

Cytotoxicity of snake venom enzymatic toxins: phospholipase A₂ and L-amino acid oxidase

Jia Jin Hiu and  Michelle Khai Khun Yap

School of Science, Monash University Malaysia, 47500 Bandar Sunway, Malaysia

Correspondence: Yap Michelle Khai Khun (yap.michelle@monash.edu)



The phospholipase A₂ (PLA₂) and L-amino acid oxidase (LAAO) are two major enzymes found in the venoms from most snake species. These enzymes have been structurally and functionally characterised for their pharmacological activities. Both PLA₂ and LAAO from different venoms demonstrate considerable cytotoxic effects on cancer cells via induction of apoptosis, cell cycle arrest and suppression of proliferation. These enzymes produce more pronounced cytotoxic effects in cancer cells than normal cells, thus they can be potential sources as chemotherapeutic agents. It is proposed that PLA₂ and LAAO contribute to an elevated oxidative stress due to their catalytic actions, for instance, the ability of PLA₂ to produce reactive oxygen species during lipolysis and formation of H₂O₂ from LAAO catalytic activity which consequently lead to cell death. Nonetheless, the cell-death signalling pathways associated with exposure to these enzymatic toxins are not fully elucidated yet. Here in this review, we will discuss the cytotoxic effects of PLA₂ and LAAO in relationship to their catalytic mechanisms and the underlying mechanisms of cytotoxic actions.

Introduction

Snake venom is a complex mixture of proteins and polypeptides with a diverse array of pharmacological activities. The proteins and polypeptides constitute ~95% of the dry weight of the venom [1]. Significant differences in venom composition have been reported between closely related species or even between the same species from different geographical origins [2,3]. Among all the venom toxins, the enzymatic toxins phospholipase A₂ (PLA₂) and L-amino acid oxidase (LAAO) are ubiquitously found in *Elapidae* and *Viperidae* whereby PLA₂ exists as the most abundant enzymatic toxins, as revealed by venom proteome (Figure 1).

PLA₂ is one of the most extensively studied enzymatic toxins in snake venoms [4]. Snake venoms are the major source of Group I and Group II secretory PLA₂. Generally, the venom PLA₂ is a small protein with the molecular mass of ~13–15 kDa. The enzyme catalyses the hydrolysis of phospholipids at *sn*-2 positions to produce lysophospholipids and free fatty acids [5]. It requires Ca²⁺ for their catalytic actions [6]. The venom PLA₂ possesses presynaptic or postsynaptic neurotoxicity [7,8], systemic or local myotoxicity [9,10], cardiotoxicity [11], platelet aggregation inhibition [12], anticoagulant [13] and oedema inducing activities [14]. The venom-induced neurotoxicity has been suggested to be attributed to the β-neurotoxin, a PLA₂ enzyme in nature that inhibits pre-synaptic neuromuscular transmission [15]. Although the molecular mechanism is not well characterised, studies have shown that the neurotoxic effects exerted by venom PLA₂ are presumably due to the influx of cytosolic calcium ions when binding to the voltage-gated ion channels on the neuronal membrane [16,17]. Besides, the PLA₂ can cause mitochondrial membrane disruption in the respiratory muscle as a result of phospholipid hydrolysis [18,19]. These events further lead to acute neuromuscular weakness, followed by flaccid paralysis [20]. In general, PLA₂ from *Elapidae* venom exists as a monomeric enzyme

Received: 8 February 2020
Revised: 7 March 2020
Accepted: 16 March 2020

Version of Record published:
8 April 2020




Figure 1. Distribution of different venom toxins from *Elapidae* and *Viperidae*

The venom toxins are coloured according to their respective pharmacological activities, whereby colour intensity indicates the dose-dependent pharmacological actions. On the other hand, different colour distributions within the same toxins correspond to the multiple biological effects exerted by the toxins [90,91]. Of all venom enzymatic toxins, the enzymes LAAO and PLA₂ exhibit cytotoxicity (represented by a yellow colour). Abbreviations: LAAO, L-amino acid oxidase; SVMP, snake venom metalloproteinase; PLA₂, phospholipase A₂; SVSP, snake venoms serine protease; 3FTX, three-finger toxin; DTX, dendrotoxin; CTL, C-type lectin; CRISP, cysteine-rich secretory protein; MTX, myotoxin.

and possesses neurotoxicity while *Viperidae* venom PLA₂ can exist in both monomer and dimer forms. The *Viperidae* monomeric PLA₂ exhibits cytotoxic effects, whereas dimeric PLA₂ possesses cytotoxic effects at a lower dose and neurotoxicity at a higher dose ([21], Figure 1).

LAAO is a flavoenzyme that catalyses the oxidative deamination of L-amino acid to α -keto acid and produces hydrogen peroxide (H₂O₂). Snake venom LAAOs display various pharmacological activities. Some enzyme LAAOs exhibit potent platelet inhibitory actions [22] while other LAAO isoforms induce platelet aggregation [23]. The antiplatelet mechanism of LAAO is attributed to the elevated production of H₂O₂, ammonia, and α -keto acid [24]. The liberated H₂O₂ affects ADP-induced platelet formation and distorts the interactions between blood coagulation factors [25,26]. In addition, LAAO also possesses antimicrobial actions [27], oedema [28], haemolysis [29] and haemorrhage [30].

Although both enzymatic toxins demonstrate various pharmacological effects, they share a similar feature whereby the products from their catalytic actions pose potent cytotoxic agents. For example, venom PLA₂ alters plasma membrane integrity in muscle cells to cause myonecrosis [31]. The membrane perturbation by PLA₂ is a secondary process to its catalytic actions on membrane phospholipids [32], indicating that venom PLA₂ exhibits remarkable cytotoxicity. On the other hand, venom LAAO has also been demonstrated to induce cell death due to the generated H₂O₂ [33–35]. Cancer is characterised by an uncontrolled cells proliferation, the ability to escape apoptosis and evading growth suppressors with active metastasis. Cancer cells differ from normal cells not only in the cellular metabolism but the lipid compositions on plasma membranes. Cancer cells have asymmetry in their membrane lipid compositions such as extracellular accumulation of phosphatidylserine [36] and higher lipid concentrations than normal cells [37]. Both enzymatic toxins exert their effects on the plasma membrane, it is thus suggested that cancer cells are more susceptible to toxins' actions.

In this review, we outline our current understanding of the structural properties and catalytic actions of both PLA₂ and LAAO. In addition, we also discuss and summarise the cytotoxic effects exerted by PLA₂ and LAAO against different cancer cells with a specific focus on the underlying mechanisms.

Phospholipase A₂

PLA₂ (EC 3.1.1.4) is an enzyme belongs to a family of lipolytic enzyme esterase which specifically catalyses the hydrolysis of the ester linkages in glycerophospholipids at the *sn*-2 position. The hydrolysis of

glycerophospholipids liberates free fatty acid, such as arachidonate and the release of lysophosphatidic which are the mediators in various biological processes.

The Ca^{2+} is a crucial cofactor for catalysis, thus the Ca^{2+} binding loop structure is highly conserved in most of the venom PLA_2 . The structure of PLA_2 has three major α -helices and two antiparallel β -sheets cross-linked by disulfide bonds [38]. The disulfide-linked α -helices (residues 37–54 and residues 90–109) form a hydrophobic channel catalytic site which facilitates the binding of phospholipid substrates [31]. The four key residues in the active site involves in the coordination of the Ca^{2+} , are His48, Asp49, Tyr52 and Asp99 via hydrogen bond formation and coupling interaction [6]. The venom PLA_2 can be classified into two major groups, namely Group I PLA_2 (GIPLA₂) and Group II PLA_2 (GIPLA₂) according to the location of disulfide bonds [6,39].

Group I PLA_2 (GIPLA₂)

The venom GIPLA₂ consists of 115–125 residues with a molecular mass of 13–15 kDa [40]. The GIPLA₂ has a single polypeptide chain containing 6–8 disulfide bridges [6]. It contains ~50% of α -helices and 10% of β -sheets [40]. The venom GIPLA₂ has an elapid loop (residues 57–59) that links the α -helices and the β -sheets [41], thus, GIPLA₂ is found ubiquitously in elapids venoms. The venom GIPLA₂ is different from mammalian pancreatic PLA_2 , which the latter enzyme has a pancreatic loop with an additional five amino acid residues at position 62–67 [42]. The GIPLA₂ is further divided into Group IA and Group IB for snake venom PLA_2 and mammalian pancreatic PLA_2 , respectively. Despite so, Group IB PLA_2 enzymes have also been identified in the venoms from *Oxyuranus scutellatus*, *Micrurus frontalis frontalis*, *Notechis scutatus* and *Ophiophagus hannah* due to the presence of the α -helix that is identical with mammalian pancreatic PLA_2 [43].

Group II PLA_2 s (GIPLA₂)

The venom GIPLA₂ is found exclusively in *Viperidae* venoms. It contains 120–125 amino acid residues and seven disulfide bonds [6]. Unlike GIPLA₂, neither the pancreatic nor elapid loops are present in GIPLA₂ enzymes. However, it possesses a C-terminal extension with a different organisation of disulfide bonds, which clearly distinguishes GIPLA₂ from GIPLA₂ [44]. In GIPLA₂, the D49 is conserved and contributes to Ca^{2+} -dependent catalytic activity [45]. Thus, GIPLA₂ is also recognised as D49 acidic PLA_2 [46].

Mechanism of cytotoxicity

PLA_2 catalyses the cleavage of the ester bond of phospholipids at the *sn*-2 site by nucleophilic attack [47]. Calcium ion, on the other hand, stabilises the negatively charged transition state by coordinating the phosphate oxygen and a carbonyl group during the catalysis [48]. Most of the biological membranes are composed of phospholipids, it is believed that PLA_2 alters the membrane fluidity and causes membrane permeabilisation, which ultimately leads to cell death. The cytotoxic effects of PLA_2 on a different cell are summarised in Table 1.

In general, venom PLA_2 variants can be classified into D49 acidic PLA_2 (Asp-49), K49 basic PLA_2 (presence of Lys-49 instead of Asp-49) and S49 PLA_2 (presence of Ser-49). The basic PLA_2 homologues, K49 and S49 PLA_2 s are responsible for many Ca^{2+} independent biological activities and thus they are catalytically inactive [45]. The D49 acidic PLA_2 is less cytotoxic than K49 basic PLA_2 , whereby acidic PLA_2 possesses higher IC_{50} than basic PLA_2 (Table 1). On the other hand, S49 PLA_2 variants have been isolated from the venoms of saw-scaled vipers *Echis* sp. [49] which also exhibit Ca^{2+} independent biological activities with potent cytotoxic effects than K49 PLA_2 (IC_{50} = 2.5–12.2 μM). Despite so, S49 PLA_2 demonstrates weaker lipolytic activity compared with K49 PLA_2 [50]. The basic PLA_2 homologues display more pronounced cytotoxic effects in cancer cells.

The C-terminal region of the PLA_2 is believed to be responsible for compromised membrane integrity and interacts with vascular endothelial growth factor receptor-2 (VEGFR-2) [51,52]. The C-terminal region of the enzyme could also bind to VEGFR-2 to inhibit angiogenesis, an essential process in cancer metastasis. Therefore, the cytotoxicity of PLA_2 is probably mediated by the interaction between the C-terminal region and the plasma membrane [53–55]. Besides, the PLA_2 -induced cytotoxicity might involve the liberated reactive oxygen species (ROS) during its phospholipid metabolism, further increases intracellular oxidative stress. Elevated oxidative stress leads to the activation of cell death pathways. Although there is no establishment of the exact pathways, it might involve the down-regulation of anti-apoptotic proteins such as Bcl2, Bcl-XL and c-FLIP [56]. There is also an increase in pro-apoptotic BAD expression and the activation of caspase 3 [56]. Moreover, PLA_2 alters the distribution of different phases in the cell cycle to cause apoptosis [57]. PLA_2 also

Table 1. The cytotoxicity of different PLA₂ from different snake species on various cell types. The IC₅₀ indicates the concentration of venom PLA₂ to kill 50% of the cell populations

Species	Types of PLA ₂	Cell types	IC ₅₀	References
<i>Bothrops asper</i>	basic PLA ₂	Mouse adrenal tumour cells	n.d.	[92]
<i>Bothrops brazili</i>	acidic PLA ₂	Jurkat human acute T-cell leukaemia cells	100.0 µg/ml	[53]
<i>Bothrops jararaca</i>	acidic PLA ₂	peripheral blood mononuclear cells (PBMC) HL60 human leukaemia cells	n.d. n.d.	[93]
<i>Bothrops jararacussu</i>	Bth TX-1	Jurkat human acute T-cell leukaemia cells Erich ascitic tumour cells SK-BR-3 human breast cancer cells MCF-7 human breast cancer cells MDAMB231 human breast cancer cells PC-12 rat adrenal medulla pheochromocytoma C2C212 murine muscle cells B16F10 mouse melanoma cells S180 murine sarcoma cells	n.d. n.d. 81.2 µg/ml 104.35 µg/ml >409 µg/ml n.d. n.d. n.d. n.d.	[54,57,94,95]
<i>Bothrops moojeni</i>	acidic PLA ₂	Jurkat human acute T-cell leukaemia cells K562-S human immortalised myelogenous leukaemia cells K562-R human immortalised myelogenous leukaemia cells	n.d. 257 µg/ml 191 µg/ml	[96] [55]
<i>Crotalus durissus terrificus</i>	Heterodimeric basic PLA ₂	Murine erythro leukemia cells SK-LU-1 human lung cancer cells Hs578T human breast cancer cells KYSE 30 oesophageal cancer cells GAMG human glioblastoma cells HCB151 glioma cells PSN-1 human pancreatic cancer cells PANC-1 pancreatic cancer cells HeLa cervical cancer cells KYSE 270 oesophageal cancer cells U373 glioma cells SiHa cervical cells	3.0–5.0 µg/ml ~4.0 µg/ml ~5.3 µg/ml 1.0 µg/ml <0.5 µg/ml 4.1 µg/ml 0.7 µg/ml <0.5 µg/ml 2.4 µg/ml 8.7 µg/ml 30.2 µg/ml >30.0 µg/ml	[97] [98] [99]
<i>Daboia siamensis</i>	dssPLA ₂	SK-MEL-28 human skin melanoma cells	n.d.	[60]
<i>Daboia russellii siamensis</i>	drsPLA ₂	SK-MEL-28 human skin melanoma cells	0.90 µg/ml	[62]
<i>Echis carinatus sochureki</i>	Ser49 PLA ₂	A549 human adenocarcinoma cells HUVEC human umbilical vein cells	8.5 µM 12.2 µM	[49]
<i>Echis coloratus</i>	Ser49 PLA ₂	A549 human adenocarcinoma cells HUVEC human umbilical vein cells	3.5 µM 4.9 µM	
<i>Echis ocellatus</i>	Ser49 PLA ₂	A549 human adenocarcinoma cells HUVEC human umbilical vein cells	5.2 µM 5.0 µM	
<i>Echis pyramidum leakeyi</i>	Ser49 PLA ₂	A549 human adenocarcinoma cells HUVEC human umbilical vein cells	2.9 µM 2.5 µM	
<i>Micrurus lemniscatus</i>	Myotoxic group I PLA ₂ (lemnitoxin)	Rat myocytes	n.d.	[100]
<i>Naja atra</i>	PLA ₂	SK-N-SH human neuroblastoma cells	n.d.	[101]
<i>Naja naja</i>	acidic PLA ₂	Erich ascitic tumour cells partially differentiated L6 rat myoblasts platelets from citrated goat blood rat pheochromocytoma PC-12 cells	n.d. n.d. n.d. n.d.	[102] [103]
<i>Naja nigricollis</i>	Nigexine (basic PLA ₂)	Epithelial FL cells C-13 T neuroblastoma cells HL60 human leukaemia cells	1.6 mM 2.9 mM 3.1 mM	[104]
<i>Vipera ammodytes ammodytes</i>	neurotoxic secretory PLA ₂	Motoneuronal NSC34 cells	n.d.	[7]

exerts genotoxic effects to induce cytotoxicity in human lymphocytes [58]. In addition, PLA₂ induces cytotoxicity through DNA damage and the formation of micronuclei [58]. The PLA₂ also significantly ameliorates the expression of proto-oncogene NOTCH1 and BRAF V600E genes in SK-MEL-28 cells [59]. As revealed by Annexin V-Propidium iodide double-staining flow cytometry, apoptosis remains as the predominant cell death mechanism in PLA₂-associated cytotoxicity [60]. It is noteworthy that, the venom PLA₂ exhibits time-dependent and dose-dependent cytotoxicity in cancer cells without any effects on normal cells [61]. Besides, the venom PLA₂ has been reported for its *in vivo* antitumour properties. The PLA₂ from *Bothrops jararacussu*, BthTX-1 could reduce the S180 tumour size by 79% in BALB/c mice [54]. In addition, Drs-PLA₂ from *Daboia russelii siamensis* has also been found to reduce tumour nodules by 65% in BALB/c mice [62]. So far, only crotoxin, a PLA₂ from *Crotalus durissus terrificus* venom undergoes phase I clinical trials which shows the objective partial response in cancer patients [63]. The cytotoxicity of PLA₂ is described in a schematic diagram (Figure 2).

L-amino acid oxidase

LAAO (EC. 1.4.3.2) is a homodimeric flavoenzyme with covalently linked-flavin adenine dinucleotides (FADs) contributes to a yellow appearance in snake venom. Each subunit in LAAO possesses a molecular mass of 50–70 kDa.




Figure 2. Summary of the cytotoxic effects of venom phospholipase A₂ in cancer cells

An example of the three-dimensional structure of a K49 basic PLA₂ from *Bothrops flavoviridis* venom is shown [Protein Data Bank accession (PDB) ID: 6AL3]. The C-terminal of PLA₂ interacts directly with the cell membrane to produce membrane perturbing effects. Accumulation of reactive oxygen species (ROS) occurs due to catalytic actions of PLA₂ on membrane phospholipids which causes cell death. The venom PLA₂ reduce the expression of anti-apoptotic proteins, for example, Bcl2, Bcl-XP, c-FLIP and proto-oncogene such as NOTCH1 and BRAF V600E. On the contrary, venom PLA₂ increases the expression of pro-apoptotic proteins BAD and caspase-3. At the same time, venom PLA₂ triggers cell cycle arrest in cancer cells. Altogether, the findings imply that apoptosis is the predominant cell death mode in PLA₂-induced cytotoxicity.

The enzyme has a molecular mass of 110–159 kDa under a native state [26,64]. The LAAO consists of three major domains, which are a substrate-binding domain, a FAD-binding domain and a helical domain ([65], Figure 3a). The substrate-binding domain is characterised by seven strands of mixed β -pleated sheet forming a pocket for substrate binding.

The FAD-binding domain is composed of two conserved motifs, including the FAD-binding motif and the GG motif, with a consensus sequence of three glycine residues (Gly) residues [66]. The first Gly is highly conserved and contributes to the positioning of the second Gly. The second Gly allows a proximity of the main chain to the negatively charged pyrophosphate of the FAD. The second Gly residue of the GG motif plays an important role in interacting with the ribose of the FAD molecule. Whereas, the third Gly promotes the close packing of α -helix and β -sheets of the motifs [67]. In brief, these interactions stabilise the tight binding of the FAD cofactor to the LAAO [68].

The helical domain forms a funnel-shaped entrance protruding into the protein core near the flavin cofactor, where the active site is located. This funnel-shaped helical domain facilitates the entry orientation of amino acid substrates through electrostatic interaction with the carboxylic groups ($-\text{COOH}$) of the substrates [65]. It appears that the key residues involved in the interaction with substrates are Arg90 and Gly 464 [65,69]. Besides, there are also two residues, His223 and Arg 322 which present at the active site to involve in the catalytic mechanisms of LAAO [69]. The LAAO exhibits high stereospecificity and enantioselectivity towards the oxidative deamination of L-amino acids due to the presence of a helical domain specifically in LAAO [70].

A catalytic reaction of LAAO comprises a reductive half reaction and the oxidation half reaction (Figure 3b). During the first half of the reduction reaction, FAD plays an important role as a cofactor. The reductive half reaction involves the abstraction of a proton from the amino group of the L-amino acid substrate by a basic His223




Figure 3. The structural and cytotoxic properties of venom L-amino acid oxidase (LAAO)

A ribbon representation of LAAO (PDD ID: 5Z2G, *Naja atra* venom) is illustrated in (a). The LAAO is a homodimeric flavoenzyme containing a substrate-binding domain (yellow colour of mixed β -pleated sheet), a flavin adenine nucleotide (FAD) binding site and a helical domain (red colour). The enzyme catalyses the oxidative deamination of L-amino acid and produces H_2O_2 as the main mediator for its cytotoxicity, as illustrated in (b). LAAO exerts apoptosis in cancer cells through extrinsic and intrinsic pathways. It is noteworthy that there is an up-regulation of CYP450 gene families to further enhance the oxidative by producing excessive ROS. On the contrary, the cell cycle arrest gene CDKN2B is down-regulated after exposure to LAAO. The CDKN2B is the main cell cycle regulator that inhibits G1 progression. It explains the role of LAAO in cell cycle arrest at the Go–G1 phase. Abbreviations: DISC-FADD, death-inducing signalling complex and Fas-associated death domain; MMP, mitochondrial membrane potential; BMP, Bcl2 modifying factor; IGFBP3, Insulin-like growth binding protein 3; PLEKHF1, Pleckstrin homology domain containing family F member 1; HSPD1, heat shock 60 kDa protein 1; SQSTM1, Sequestosome 1; MLF1, myeloid leukaemia factor 1; KLF10, Kruppel-like factor 10; CDKN2B, Cyclin-dependent kinase inhibitor 2B.

Table 2. The cytotoxicity of different LAO from different snake species on various cell types. The IC₅₀ indicates the concentration of venomous LAO to kill 50% of the cell populations

Species	Name of LAO	Cell type	IC ₅₀	References	
<i>Agkistrodon acutus</i>	ACTX-6	A549 human lung cancer cells	20 µg/ml	[84]	
	ACTX-8	HeLa cervical cancer cells		[75]	
<i>Agkistrodon contortrix laticinctus</i>	ACL LAO	HL60 human leukaemia cells	n.d.	[30]	
<i>Agkistrodon halys</i>	AhLAAO	L1210 mouse lymphocytic leukaemia	n.d.	[80]	
		MOLT-4 human lymphoblastic leukaemia cells			
		HL60 human leukaemia cells			
		RPMI 1788 human peripheral blood			
<i>Bothrops atrox</i>	BatroxLAAO	A549 human lung cancer cells	n.d.	[105]	
		HL60 human leukaemia cells	50 µg/ml		[78,83]
		B16F10 mouse skin melanoma	25 µg/ml		
		PC-12 rat adrenal medulla pheochromocytoma			
		Jurkat human acute T-cell leukaemia cells			
Normal human keratinocytes	5.1 µg/ml	[33]			
<i>Bothrops insularis</i>	BiLAO	Tubular		[106]	
<i>Bothrops jararaca</i>	BjarLAAO-I	Ehrlich ascites tumour cells	n.d.	[107]	
<i>Bothrops leucurus</i>	BI-LAAO	MKN-45 gastric cancer cells	n.d.	[34]	
		HuTu human duodenocarcinoma			
		RKO human colorectal cells			
		LL-24 human fibroblast cells			
<i>Bothrops moojeni</i>	BmoolAAO-I	EAT cells		[23]	
		HL60 human leukaemia cells			
<i>Bothrops pirajai</i>	BpirLAAO-I	HL60 human leukaemia cells	n.d.	[79]	
		BCR-ABL human leukaemia cells			
		HL60 human leukaemia cells			
		Jurkat human acute T-cell leukaemia cells	n.d.		[76]
		SKBR-3 human breast cancer cells			
		S180 murine sarcoma			
Ehrlich ascites tumour cell					
<i>Bungarus fasciatus</i>	BF-LAAO	A549 human lung cancer cells	n.d.	[28]	
<i>Calloselasma rhadostoma</i>	CR-LAAO	Jurkat human acute T-cell leukaemia cells	n.d.	[85]	
<i>Crotalus atrox</i>	Apoxin I	HL60 human leukaemia cells	n.d.	[81]	
		A2780 human ovarian cancer cells			
		293T human embryonic kidney cells			
		KN-3 odontoblast cells			
<i>Eristocophis macmahoni</i>	LNV-LAO	MM6 human monocytic cells		[64]	
<i>Lachesis muta</i>	LmlAAO	AGS gastric adenocarcinoma	22.7 µg/ml	[108]	
		MCF-7 human breast cells	1.41 µg/ml		
		VERO normal epithelial monkey kidney	0.83 µg/ml		[35]
		EA, hy926 human umbilical vein			
		HeLa cervical cancer cells			
		MGSO-3 human breast cancer tissue			
normal human keratinocyte					
<i>Ophiophagus hannah</i>	OH-LAAO	B16F10 murine melanoma	0.17 µg/ml	[109]	
		HT-1080 human fibrosarcoma	0.6 µg/ml		
		CHO Chinese hamster ovary cells	0.3 µg/ml		
		murine epithelial cells Balb/3T3	0.45 µg/ml		
		PC3 human prostate cancer cells	0.05 µg/ml		[87]
		MCF-7 human breast cancer cells	0.04 µg/ml		[110]
		A549 human lung cancer cells	0.05 µg/ml		[110]
<i>Trimeresurus flavoviridis</i>	OHAP-1	rat C6 glioma cells RBR 17T	n.d.	[111]	
human glioma U251					
<i>Trimeresurus stejnegeri</i>	TSV-LAO	C8166 human T cell leukaemia	24 nM	[112]	
<i>Vipera berus berus</i>	VB-LAAO	HeLa cervical cancer cells	n.d.	[22]	
		K562 human leukaemia cells			

residue [65]. Concomitantly, an imino intermediate is formed when a hydride is transferred from α carbon of the substrate to the N5 of the FAD isoalloxazine ring. The cofactor FADH₂ is produced in this reaction. The imino acid is further hydrolysed non-enzymatically into α -keto acid and ammonia [71]. The second oxidative half reaction involves the oxidation of the FADH₂ into FAD and at the same time, generating H₂O₂ [72]. This reaction completes the LAAO catalytic cycle as the FAD cofactor is regenerated for subsequent cycles [73].

Mechanism of cytotoxicity

Extensive studies have demonstrated that snake venom LAAOs induce cytotoxic effects, particularly on cancer cell lines (Table 2). However, the actual cytotoxic mechanism is poorly understood. Most of the hypotheses are based on the accumulated H₂O₂ generated during the LAAO catalytic activity, which leads to oxidative stress [22,74,75]. This theory is further supported by a few studies which have demonstrated a reduction in the cytotoxic effect of LAAO upon exposure to glutathione (GSH) or catalase, which inhibit the H₂O₂ activity [34,75,76].

The liberated H₂O₂ accumulates as ROS to cause direct deterioration of the cell membranes. The oxidative stress by H₂O₂ could also lead to the dissipation of MMP to induce translocation of cytochrome c to cytosol [77]. Cytochrome c then activates caspase-9, an initiator caspase presence in the intrinsic mitochondrial-mediated apoptosis. The p53 apoptotic proteins are found to be substantially expressed in the presence of LAAO, followed by translocation of the cytoplasmic Bax protein to mitochondria to activate the downstream apoptotic pathways [75]. Furthermore, LAAO has been reported to activate another initiator caspase-8 in the extrinsic death-receptor apoptosis before downstream activation of caspase-3 (the executioner phase of apoptosis) [78,79]. Extrinsic apoptosis requires ligands–death receptor interactions to form DISC-FADD, followed by cleavage of pro-caspase 8 to active caspase-8. However, it is uncertain if LAAO interacts with the death receptors for the occurrence of the extrinsic pathway. On the other hand, caspase-3 is responsible for the endpoint apoptotic features such as chromatin condensation (karyorrhexis) and DNA fragmentation. The findings thus conclude that LAAO exerts apoptosis through extrinsic and intrinsic pathways.

Besides, LAAO from *Agkistrodon halys* venom displays cytotoxicity on murine lymphoblastic leukaemia cells (L1210) with prominent apoptotic features such as DNA fragmentation [80]. Similarly, apoxin 1, a type of LAAO from *Crotalus atrox* venom also induces DNA fragmentation in human umbilical endothelial cells, HL-60 (human leukaemia) A2780 (human ovarian carcinoma) and NK-3 (rat endothelial cells) due to elevated H₂O₂ levels [81]. The ACL-LAAO isolated from *Agkistrodon contortrix* venom has also been demonstrated to cause DNA fragmentation in HL60 cells [30]. On the other hand, LAAO from *Ophiophagus hannah* venom was found to alter several apoptotic, autophagic and cell cycle-related genes, as a result of accumulated H₂O₂ released from the enzyme action [82]. Furthermore, the LAAO also significantly up-regulates cytochrome P450 genes to further increase intracellular ROS levels [82]. Similar to PLA₂, venom LAAO also induces cell cycle arrest in cancer cell lines. In a study on *Bothrops atrox* snake venom LAAO treated HL-60 cells, the BatroxLAAO exerts an arrest in the Go/G1 phase with a decrease in S and G2/M phases [83]. Another LAAO from *Agkistrodon acutus* venom, namely ACTX-6 also elicits cell cycle arrest in A549 cells [84]. Collectively, these findings suggest that venom LAAO activates both intrinsic and extrinsic apoptotic pathways (Figure 3).

In addition to apoptosis, the venom LAAO exhibits a dose-dependent transition of apoptosis to necrosis when its concentration increases [22,33,80,83]. This is presumably related to the levels of H₂O₂ produced by the enzyme, as the treatment with catalase significantly reduced the number of necrotic cells [85].

Although apoptosis remains as the predominant cell death mode in LAAO-induced cytotoxicity in cancer cells, the venom LAAO is able to cause autophagy in normal human keratinocyte [33]. Autophagy refers to a self-degenerative cell death process in which cellular components are degraded in autophagic vacuoles of dying cells [86]. The LAAO-induced cytotoxic effects are dose dependent and follow a sequential manner of cells undergoing autophagy, apoptosis to necrosis within 24 h [33,35]. On the other hand, preclinical trials of LAAO from *Ophiophagus hannah* revealed that LAAO suppresses PC-3 Solid Tumour Growth in a tumour xenograft mouse model [87]. The venom LAAO exhibits selectivity towards cancer cells and relatively non-toxic to normal cells [79,87–89].

Conclusion

The enzymatic toxins, PLA₂ and LAAO from snake venoms, exhibit pronounced cytotoxic effects mainly on cancer cells. They suppress cancer cells proliferation, induce apoptosis and cell cycle arrest, although necrosis and autophagy cell death are also observed. The C-terminal region of PLA₂ is suggested to contribute to its

cytotoxicity upon interaction with the cell membranes. On the other hand, LAAO is known to produce notable levels of H_2O_2 through its enzymatic reaction. Therefore, the enzymes are known to cause the accumulation of ROS which eventually leads to cell death. Besides cytotoxicity, PLA_2 and LAAO also possess anticoagulant activity which could be promising candidates in cancer research as venous thromboembolism is often observed in cancer. The exact modes cell death elicited by the enzymes, especially the potential agonistic actions on the death receptors, are not well established. Therefore, elucidation of the possible enzymes–receptors interactions is required in future studies. While considering the potential anticancer effects of both enzymes, we must not forget to ascertain the selectivity of the enzymes towards cancer cells only. Since non-cancer cells are less susceptible to both enzymes, it is most likely that the cytotoxic actions of PLA_2 and LAAO are selective to cancer cells only. Nevertheless, before these enzymatic toxins can be developed into chemotherapeutic agent, their efficacy, potency and safety need to be established while considering new approaches for targeted delivery, these include formulation into nanoparticles or conjugation with ligands or monoclonal antibodies which recognises targeted cancer cells.

Perspectives

- Importance of the field: Although both enzymatic toxins exhibit various pharmacological actions, we should not neglect their cytotoxic properties on cancer cells. Both PLA_2 and LAAO produce oxidative stress and trigger cell cycle arrest and apoptosis in cancer cells, thereby suggesting their potential applications as anticancer lead molecules.
- Current status: Despite well documented structural and catalytic properties of both enzymes, their cytotoxic actions remain superficial without in-depth analysis on the specific cell-death signalling pathways. It remains ambiguous if both PLA_2 and LAAO interact directly with the surface cell death receptors to induce cytotoxicity.
- Future direction: The potential target actions of PLA_2 and LAAO on cell surface death receptors remain poorly understood. Cancer cells possess abnormalities in cell surface death receptors, for instance, down-regulation of TRAIL receptor DR4, mutated DR5 as well as over-expression of TRAIL decoy and Fas decoy. Thus, investigation of enzymes–death receptor interaction will distinguish the selectivity of the enzymes targeting cancer cells. This is attainable via *in-silico* docking analysis and chemical cross-link mass spectrometry to detect enzyme–receptor interactomes which enables the annotation of signalling pathways targeted by enzymes PLA_2 and LAAO during cytotoxicity.

Open Access

Open access for this article was enabled by the participation of Monash University in an all-inclusive *Read & Publish* pilot with Portland Press and the Biochemical Society under a transformative agreement with CAUL.

Competing Interests

The authors declare that there are no competing interests associated with the manuscript.

Author Contribution

J.J.H. and M.K.K.Y. wrote the manuscript draft, M.K.K.Y. edited the manuscript. All authors approved the final article.

Abbreviations

FADs, flavin adenine dinucleotides; LAAO, L -amino acid oxidase; PLA_2 , phospholipase A_2 ; ROS, reactive oxygen species.

References

- 1 Tu, A.T. (1996) Overview of snake venom chemistry. In *Natural Toxins 2 Advances in Experimental Medicine and Biology* (Singh, B.R., Tu, A.T., eds), vol. 391, pp. 37–62, Boston, MA, Springer

- 2 Queiroz, G.P., Pessoa, L.A., Portaro, F.C.V., MdFD, F. and Tambourg, D.V. (2008) Interspecific variation in venom composition and toxicity of Brazilian snakes from *Bothrops* genus. *Toxicon* **52**, 842–851 <https://doi.org/10.1016/j.toxicon.2008.10.002>
- 3 Salazar, A.M., Guerrero, B., Cantu, B., Cantu, E., Rodríguez-Acosta, A., Pérez, J.C. et al. (2009) Venom variation in hemostasis of the southern Pacific rattlesnake (*Crotalus oreganus helleri*): isolation of hellerase. *Comp. Biochem. Physiol. C Toxicol. Pharmacol.* **149**, 307–316 <https://doi.org/10.1016/j.cbpc.2008.08.007>
- 4 Mackessy, S.P. (2002) Biochemistry and pharmacology of colubrid snake venoms. *J. Toxicol. Toxin Rev.* **21**, 43–83 <https://doi.org/10.1081/TXR-120004741>
- 5 Kini, R.M. (1997) *Venom Phospholipase A2 Enzymes: Structure, Functions and Mechanisms*, John Wiley & Son Limited, Hoboken, NJ
- 6 Doley, R., Zhou, X. and Kini, M. (2010) Snake venom phospholipase A2 enzymes. In *Handbook of Venoms and Toxins of Reptiles* (Mackessy, S.P., ed.), pp. 174–195, CRC Press, Boca Raton
- 7 Praznikar, Z.J., Petan, T. and Pungercar, J. A neurotoxic secretory phospholipase A₂ induces apoptosis in motoneuron-like cells. *Ann NY Acad Sci.* 2009; **1152**:215–224. <https://doi.org/10.1111/j.1749-6632.2008.03999.x>
- 8 Rouault, M., Rash, L.D., Escoubas, P., Boilard, E., Bollinger, J., Lomonte, B. et al. (2006) Neurotoxicity and other pharmacological activities of the snake venom phospholipase A₂ OS2: the N-terminal region is more important than enzymatic activity. *Biochemistry* **45**, 5800–5816 <https://doi.org/10.1021/bi060217r>
- 9 Andrião-Escarso, S.H., Soares, A.M., Rodrigues, V.M., Angulo, Y., Díaz, C., Lomonte, B. et al. (2000) Myotoxic phospholipases A₂ in *bothrops* snake venoms: effect of chemical modifications on the enzymatic and pharmacological properties of bothropstoxins from *Bothrops jararacussu*. *Biochimie* **82**, 755–763 [https://doi.org/10.1016/S0300-9084\(00\)01150-0](https://doi.org/10.1016/S0300-9084(00)01150-0)
- 10 Gutiérrez, J.M., Ponce-Soto, L.A., Marangoni, S. and Lomonte, B. (2008) Systemic and local myotoxicity induced by snake venom group II phospholipases A₂: comparison between crotoxin, crotoxin B and a Lys49 PLA₂ homologue. *Toxicon* **51**, 80–92 <https://doi.org/10.1016/j.toxicon.2007.08.007>
- 11 Zhang, H.L., Xu, S.J., Wang, Q.Y., Song, S.Y., Shu, Y.Y. and Lin, Z.J. (2002) Structure of a cardiotoxic phospholipase A₂ from *Ophiophagus hannah* with the “pancreatic loop”. *J. Struct. Biol.* **138**, 207–215 [https://doi.org/10.1016/S1047-8477\(02\)00022-9](https://doi.org/10.1016/S1047-8477(02)00022-9)
- 12 Satish, S., Tejaswini, J., Krishnakantha, T.P. and Gowda, T.V. (2004) Purification of a class B1 platelet aggregation inhibitor phospholipase A₂ from Indian cobra (*Naja naja*) venom. *Biochimie* **86**, 203–210 <https://doi.org/10.1016/j.biochi.2004.02.003>
- 13 Zhao, K., Zhou, Y. and Lin, Z. (2000) Structure of basic phospholipase A₂ from *Agkistrodon halys pallas*: implications for its association, hemolytic and anticoagulant activities. *Toxicon* **38**, 901–916 [https://doi.org/10.1016/S0041-0101\(99\)00193-2](https://doi.org/10.1016/S0041-0101(99)00193-2)
- 14 Yamaguchi, Y., Shimohigashi, Y., Chijiwa, T., Nakai, M., Ogawa, T., Hattori, S. et al. (2001) Characterization, amino acid sequence and evolution of edema-inducing, basic phospholipase A₂ from *Trimeresurus flavoviridis* venom. *Toxicon* **39**, 1069–1076 [https://doi.org/10.1016/S0041-0101\(00\)00250-6](https://doi.org/10.1016/S0041-0101(00)00250-6)
- 15 Šribar, J., Oberčkal, J. and I, K. (2014) Understanding the molecular mechanism underlying the presynaptic toxicity of secreted phospholipases A₂: an update. *Toxicon* **89**, 9–16 <https://doi.org/10.1016/j.toxicon.2014.06.019>
- 16 Rigoni, M., Pizzo, P., Schiavo, G., Weston, A.E., Zatti, G., Caccin, P. et al. (2007) Calcium influx and mitochondrial alterations at synapses exposed to snake neurotoxins or their phospholipid hydrolysis products. *J. Biochem.* **282**, 11238–11245
- 17 Vulfius, C.A., Kasheverov, I.E., Kryukova, E.V., Spirova, E.N., Shelukhina, I.V., Starkov, V.G. et al. (2017) Pancreatic and snake venom presynaptically active phospholipases A₂ inhibit nicotinic acetylcholine receptors. *PLoS One* **12**, e0186206 <https://doi.org/10.1371/journal.pone.0186206>
- 18 Rigoni, M., Paoli, M., Milanesi, E., Caccin, P., Rasola, A., Bernardi, P. et al. (2008) Snake phospholipase A₂ neurotoxins enter neurons, bind specifically to mitochondria, and open their transition pores. *J. Biochem.* **283**, 34013–34020
- 19 Paoli, M., Rigoni, M., Koster, G., Rossetto, O., Montecucco, C. and Postle, A.D. (2009) Mass spectrometry analysis of the phospholipase A₂ activity of snake pre-synaptic neurotoxins in cultured neurons. *J. Neurochem.* **111**, 737–744 <https://doi.org/10.1111/j.1471-4159.2009.06365.x>
- 20 Ranawaka, U.K., Laloo, D.G. and de Silva, H.J. (2013) Neurotoxicity in snakebite—the limits of our knowledge. *PLoS Negl. Trop. Dis.* **7**, e2302 <https://doi.org/10.1371/journal.pntd.0002302>
- 21 Gutiérrez, J.M., Calvete, J.J., Habib, A.G., Harrison, R.A., Williams, D.J. and Warrell, D.A. (2017) Snakebite envenoming. *Nat. Rev. Dis. Primers* **3**, 17079 <https://doi.org/10.1038/nrdp.2017.79>
- 22 Samel, M., Vija, H., Rönnholm, G., Siigur, J., Kalkkinen, N. and Siigur, E. (2006) Isolation and characterization of an apoptotic and platelet aggregation inhibiting L-amino acid oxidase from *Vipera berus berus* (common viper) venom. *Biochim. Biophys. Acta* **1764**, 707–714 <https://doi.org/10.1016/j.bbapap.2006.01.021>
- 23 Stábéli, R.G., Sant’Ana, C.D., Ribeiro, P.H., Costa, T.R., Ticli, F.K., Pires, M.G. et al. (2007) Cytotoxic L-amino acid oxidase from *Bothrops moojeni*: biochemical and functional characterization. *Int. J. Biol. Macromol.* **41**, 132–140 <https://doi.org/10.1016/j.ijbiomac.2007.01.006>
- 24 de Queiroz, M.R., de Sousa, B.B., da Cunha Pereira, D.F., Mamede, C.C.N., Matias, M.S., de Moraes, N.C.G. et al. (2017) The role of platelets in homeostasis and the effects of snake venom toxins on platelet function. *Toxicon* **133**, 33–47 <https://doi.org/10.1016/j.toxicon.2017.04.013>
- 25 Belisario, M.A., Tafuri, S., Di Domenico, C., Squillacioti, C., Della Morte, R., Lucisano, A. et al. (2000) H₂O₂ activity on platelet adhesion to fibrinogen and protein tyrosine phosphorylation. *Biochim. Biophys. Acta* **1495**, 183–193 [https://doi.org/10.1016/S0167-4889\(99\)00160-3](https://doi.org/10.1016/S0167-4889(99)00160-3)
- 26 Du, X.Y. and Clemetson, K.J. (2002) Snake venom L-amino acid oxidases. *Toxicon* **40**, 659–665 [https://doi.org/10.1016/S0041-0101\(02\)00102-2](https://doi.org/10.1016/S0041-0101(02)00102-2)
- 27 Rodrigues, R.S., da Silva, J.F., Boldrini França, J., Fonseca, F.P.P., Otaviano, A.R., Henrique Silva, F. et al. (2009) Structural and functional properties of Bp-LAAO, a new L-amino acid oxidase isolated from *Bothrops pauloensis* snake venom. *Biochimie* **91**, 490–501 <https://doi.org/10.1016/j.biochi.2008.12.004>
- 28 Wei, J.F., Yang, H.W., Wei, X.L., Qiao, L.Y., Wang, W.Y. and He, S.H. (2009) Purification, characterization and biological activities of the L-amino acid oxidase from *Bungarus fasciatus* snake venom. *Toxicon* **54**, 262–271 <https://doi.org/10.1016/j.toxicon.2009.04.017>
- 29 Ciscotto, P., de Avila RA, M., Coelho, E.A.F., Oliveira, J., Diniz, C.G., Farias, L.M. et al. (2009) Antigenic, microbicidal and antiparasitic properties of an L-amino acid oxidase isolated from *Bothrops jararaca* snake venom. *Toxicon* **53**, 330–341 <https://doi.org/10.1016/j.toxicon.2008.12.004>
- 30 Souza, D.H., Eugenio, L.M., Fletcher, J.E., Jiang, M.S., Garratt, R.C., Oliva, G. et al. (2009) Isolation and structural characterization of a cytotoxic L-amino acid oxidase from *Agkistrodon contortrix laticinctus* snake venom: preliminary crystallographic data. *Arch. Biochem. Biophys.* **1999368**, 285–290
- 31 Montecucco, C., Gutiérrez, J.M. and Lomonte, B. (2008) Cellular pathology induced by snake venom phospholipase A₂ myotoxins and neurotoxins: common aspects of their mechanisms of action. *Cell. Mol. Life Sci.* **65**, 2897–2912 <https://doi.org/10.1007/s00018-008-8113-3>

- 32 Gutiérrez, J.M. and Ownby, C.L. (2003) Skeletal muscle degeneration induced by venom phospholipases A₂: insights into the mechanisms of local and systemic myotoxicity. *Toxicon* **42**, 915–931 <https://doi.org/10.1016/j.toxicon.2003.11.005>
- 33 Costal-Oliveira, F., Stransky, S., Guerra-Duarte, C., de Souza DL, N., Vivas-Ruiz, D.E., Yarlequé, A. et al. (2019) L-amino acid oxidase from *Bothrops atrox* snake venom triggers autophagy, apoptosis and necrosis in normal human keratinocytes. *Sci. Rep.* **9**, 781 <https://doi.org/10.1038/s41598-018-37435-4>
- 34 Naumann, G.B., Silva, L.F., Silva, L., Faria, G., Richardson, M., Evangelista, K. et al. (2011) Cytotoxicity and inhibition of platelet aggregation caused by an L-amino acid oxidase from *Bothrops leucurus* venom. *Biochim. Biophys. Acta* **1810**, 683–694 <https://doi.org/10.1016/j.bbagen.2011.04.003>
- 35 Stransky, S., Costal-Oliveira, F., Lopes-de-Souza, L., Guerra-Duarte, C., Chávez-Olórtegui, C. and Braga, V.M.M. (2018) In vitro assessment of cytotoxic activities of *Lachesis muta muta* snake venom. *PLoS Negl. Trop. Dis.* **12**, e0006427 <https://doi.org/10.1371/journal.pntd.0006427>
- 36 Tan, L.T.H., Chan, K.G., Pusparajah, P., Lee, W.L., Chuah, L.H., Khan, T.M. et al. (2017) Targeting membrane lipid a potential cancer cure? *Front. Pharmacol.* **8**, 12 <https://doi.org/10.3389/fphar.2017.00012>
- 37 Costa, T.R., Burin, S.M., Menaldo, D.L., de Castro, F.A. and Sampaio, S.V. (2014) Snake venom L-amino acid oxidases: an overview on their antitumor effects. *J. Venom. Anim. Toxins Incl. Trop. Dis.* **20**, 23 <https://doi.org/10.1186/1678-9199-20-23>
- 38 Scott, D. (1997). Phospholipase A₂: structure and catalytic properties. In *Venom Phospholipase A2 Enzymes: Structure, Function and Mechanism* (Kini, R.M., ed.), pp. 97–128, John Wiley & Son Limited, Chichester
- 39 Six, D.A. and Dennis, E.A. (2000) The expanding superfamily of phospholipase A₂ enzymes: classification and characterization. *Biochim. Biophys. Acta* **1488**, 1–19 [https://doi.org/10.1016/S1388-1981\(00\)00105-0](https://doi.org/10.1016/S1388-1981(00)00105-0)
- 40 Harris, J.B. and Scott-Davey, T. (2013) Secreted phospholipases A₂ of snake venoms: effects on the peripheral neuromuscular system with comments on the role of phospholipases A₂ in disorders of the CNS and their uses in industry. *Toxins* **5**, 2533–2571 <https://doi.org/10.3390/toxins5122533>
- 41 Carredano, E., Westerlund, B., Persson, B., Saarinen, M., Ramaswamy, S., Eaker, D. et al. (1998) The three-dimensional structures of two toxins from snake venom throw light on the anticoagulant and neurotoxic sites of phospholipase A₂. *Toxicon* **36**, 75–92 [https://doi.org/10.1016/S0041-0101\(97\)00051-2](https://doi.org/10.1016/S0041-0101(97)00051-2)
- 42 Davidson, F.F. and Dennis, E.A. (1990) Evolutionary relationships and implications for the regulation of phospholipase A₂ from snake venom to human secreted forms. *J. Mol. Evol.* **31**, 228–238 <https://doi.org/10.1007/BF02109500>
- 43 Huang, M.Z., Gopalakrishnakone, P., Chung, M.C. and Kini, R.M. (1997) Complete amino acid sequence of an acidic, cardiotoxic phospholipase A₂ from the venom of *Ophiophagus hannah* (King cobra): a novel cobra venom enzyme with "pancreatic loop". *Arch. Biochem. Biophys.* **338**, 150–156 <https://doi.org/10.1006/abbi.1996.9814>
- 44 Xiao, H., Pan, H., Liao, K., Yang, M. and Huang, C. (2017) Snake Venom PLA₂, a promising target for broad-spectrum antivenom drug development. *Biomed Res Int.* **2017**, 6592820 <https://doi.org/10.1155/2017/6592820>
- 45 Ward, R.J., Chioato, L., de Oliveira, A.H.C., Ruller, R. and Sá, J.M. (2002) Active-site mutagenesis of a Lys49-phospholipase A₂: biological and membrane-disrupting activities in the absence of catalysis. *Biochem. J.* **362**(Pt 1), 89–96 <https://doi.org/10.1042/bj3620089>
- 46 Matsui, T., Kamata, S., Ishii, K., Maruno, T., Ghanem, N., Uchiyama, S. et al. (2019) SDS-induced oligomerization of Lys49-phospholipase A PLA₂ from snake venom. *Sci. Rep.* **9**, 2330 <https://doi.org/10.1038/s41598-019-38861-8>
- 47 Kang, T.S., Georgieva, D., Genov, N., Murakami, M.T., Sinha, M., Kumar, R.P. et al. (2011) Enzymatic toxins from snake venom: structural characterization and mechanism of catalysis. *FEBS J.* **278**, 4544–4576 <https://doi.org/10.1111/j.1742-4658.2011.08115.x>
- 48 Scott, D.L., White, S.P., Otwinowski, Z., Yuan, W., Gelb, M.H. and Sigler, P.B. (1990) Interfacial catalysis: the mechanism of phospholipase A₂. *Science* **250**, 1541–1546 <https://doi.org/10.1126/science.2274785>
- 49 Conlon, J.M., Attoub, S., Arafat, H., Mechkarska, M., Casewell, N.R., Harrison, R.A. et al. (2013) Cytotoxic activities of [Ser⁴⁹] phospholipase A₂ from the venom of the saw-scaled vipers *Echis ocellatus*, *Echis pyramidum leakeyi*, *Echis carinatus sochureki*, and *Echis coloratus*. *Toxicon* **71**, 96–104 <https://doi.org/10.1016/j.toxicon.2013.05.017>
- 50 Petan, T., Krizaj, I. and Pungercar, J. (2007) Restoration of enzymatic activity in a Ser-49 phospholipase A₂ homologue decreases its Ca²⁺-independent membrane-damaging activity and increases its toxicity. *Biochemistry* **46**, 12795–12809 <https://doi.org/10.1021/bi701304e>
- 51 Lomonte, B., Angulo, Y. and Calderón, L. (2003) An overview of lysine-49 phospholipase A₂ myotoxins from crotalid snake venoms and their structural determinants of myotoxic action. *Toxicon* **42**, 885–901 <https://doi.org/10.1016/j.toxicon.2003.11.008>
- 52 Fujisawa, D., Yamazaki, Y., Lomonte, B. and Morita, T. (2008) Catalytically inactive phospholipase A₂ homologue binds to vascular endothelial growth factor receptor-2 via a C-terminal loop region. *Biochem J.* **411**, 515–522 <https://doi.org/10.1042/BJ20080078>
- 53 Costa, T.R., Menaldo, D.L., Oliveira, C.Z., Santos-Filho, N.A., Teixeira, S.S., Nomizo, A. et al. (2008) Myotoxic phospholipases A₂ isolated from *Bothrops brazili* snake venom and synthetic peptides derived from their C-terminal region: cytotoxic effect on microorganism and tumour cells. *Peptides* **29**, 1645–1656 <https://doi.org/10.1016/j.peptides.2008.05.021>
- 54 Gebrim, L.C., Marcussi, S., Menaldo, D.L., de Menezes, C.S.R., Nomizo, A., Hamaguchi, A. et al. (2009) Antitumor effects of snake venom chemically modified Lys49 phospholipase A₂-like BthTX-I and a synthetic peptide derived from its C-terminal region. *Biologicals* **37**, 222–229 <https://doi.org/10.1016/j.biologicals.2009.01.010>
- 55 Lomonte, B., Angulo, Y. and Moreno, E. (2010) Synthetic peptides derived from the C-terminal region of Lys49 phospholipase A₂ homologues from *viperidae* snake venoms: biomimetic activities and potential applications. *Curr. Pharm. Des.* **16**, 3224–3230 <https://doi.org/10.2174/138161210793292456>
- 56 Benati, R.B., Costa, T.R., MdC, C., Sampaio, S.V., de Castro, F.A. and Burin, S.M. (2018) Cytotoxic and pro-apoptotic action of MjTX-I, a phospholipase A₂ isolated from *Bothrops moojenisnake* venom, towards leukemic cells. *J. Venom. Anim. Toxins Incl. Trop. Dis.* **24**, 40 <https://doi.org/10.1186/s40409-018-0180-9>
- 57 da Silva C, P., Costa, T.R., Paiva, R.M.A., Cintra, A.C.O., Menaldo, D.L., Antunes, L.M.G. et al. (2015) Antitumor potential of the myotoxin BthTX-I from *Bothrops jararacussu* snake venom: evaluation of cell cycle alterations and death mechanisms induced in tumour cell lines. *J. Venom. Anim. Toxins* **21**, 44 <https://doi.org/10.1186/s40409-015-0044-5>
- 58 Marcussi, S., Santos, P.R.S., Menaldo, D.L., Silveira, L.B., Santos-Filho, N.A., Mazzi, M.V. et al. (2011) Evaluation of the genotoxicity of *Crotalus durissus terrificus* snake venom and its isolated toxins on human lymphocytes. *Mutat. Res.* **724**, 59–63 <https://doi.org/10.1016/j.mrgentox.2011.06.004>
- 59 Khunsap, S., Khow, O., Buranapraditkun, S., Suntrarachun, S., Puthong, S. and Boonchang, S. (2016) Anticancer properties of phospholipase A₂ from *Daboia siamensis* venom on human skin melanoma cells. *J. Venom. Anim. Toxins Incl. Trop. Dis.* **22**, 7 <https://doi.org/10.1186/s40409-016-0061-z>

- 60 Marcussi, S., Stábéli, R.G., Santos-Filho, N.A., Menaldo, D.L., Silva Pereira, L.L., Zuliani, J.P. et al. (2013) Genotoxic effect of *Bothrops* snake venoms and isolated toxins on human lymphocyte DNA. *Toxicon* **65**, 9–14 <https://doi.org/10.1016/j.toxicon.2012.12.020>
- 61 Tran, T.V., Siniavin, A.E., Hoang, A.N., Le, M.T.T., Pham, C.D., Phung, T.V. et al. (2019) Phospholipase A₂ from krait *Bungarus fasciatus* venom induces human cancer cell death in vitro. *PeerJ* **7**, e8055 <https://doi.org/10.7717/peerj.8055>
- 62 Khunsap, S., Pakmanee, N., Khoo, O., Chanhome, L., Sitprijia, V., Suntravat, M. et al. (2011) Purification of a phospholipase A₂ from *Daboia russelii siamensis* venom with anticancer effects. *J. Venom. Res.* **2**, 42–51
- 63 Cura, J.E., Blanzaco, D.P., Brisson, C., Cura, M.A., Cabrol, R., Larrateguy, L. et al. (2002) Phase I and pharmacokinetics study of crotoxin (cytotoxic PLA₂, NSC-624244) in patients with advanced cancer. *Clin. Cancer Res.* **8**, 1033–1041 PMID:11948110
- 64 Ali, S.A., Stoeva, S., Abbasi, A., Alam, J.M., Kayed, R., Faigle, M. et al. (2000) Isolation, structural, and functional characterization of an apoptosis-inducing L-amino acid oxidase from leaf-nosed viper (*Eristocophis macmahoni*) snake venom. *Arch. Biochem. Biophys.* **384**, 216–226 <https://doi.org/10.1006/abbi.2000.2130>
- 65 Pawelek, P.D., Cheah, J., Coulombe, R., Macheroux, P., Ghisla, S. and Vrielink, A. (2000) The structure of L-amino acid oxidase reveals the substrate trajectory into an enantiomerically conserved active site. *EMBO J.* **19**, 4204–4215 <https://doi.org/10.1093/emboj/19.16.4204>
- 66 Hanukoglu, I. (2015) Proteopedia: Rossmann fold: A beta-alpha-beta fold at dinucleotide binding sites. *Biochem. Mol. Biol. Edu.* **43**, 206–209 <https://doi.org/10.1002/bmb.20849>
- 67 Dym, O. and Eisenberg, D. (2001) Sequence-structure analysis of FAD-containing proteins. *Protein Sci.* **10**, 1712–1728 <https://doi.org/10.1110/ps.12801>
- 68 Suwannapan, W., Chumnanpuen, P. and E-Kobon, T. (2018) Amplification and bioinformatics analysis of conserved FAD-binding region of L-amino acid oxidase LAAO genes in gastropods compared to other organisms. *Comput. Struct. Biotech* **16**, 98–107 <https://doi.org/10.1016/j.csbj.2018.02.008>
- 69 Moustafa, I.M., Foster, S., Lyubimov, A.Y. and Vrielink, A. (2006) Crystal structure of LAAO from *Calloselasma rhodostoma* with an L-phenylalanine substrate: insights into structure and mechanism. *J. Mol. Biol.* **364**, 991–1002 <https://doi.org/10.1016/j.jmb.2006.09.032>
- 70 Umhau, S., Diederichs, K., Welte, W., Ghisla, S., Pollegioni, L., Molla, G. et al. (1999) Very high resolution crystal structure of D-amino acid oxidase. Insights into the reaction mechanisms and mode of ligand binding. In *Flavins and Flavoproteins* (Ghisla, S., Kroneck, P., Macheroux, P., Sund, H., eds.), pp. 567–570, Rudolf Weber, Berlin
- 71 Gaweska, H. and Fitzpatrick, P.F. (2011) Structures and mechanism of the monoamine oxidase family. *Biomol. Concepts* **2**, 365–377 <https://doi.org/10.1515/BMC.2011.030>
- 72 Macheroux, P., Seth, O., Bollschweiler, C., Schwarz, M., Kurfürst, M., Au, L.C. et al. (2001) L-amino-acid oxidase from the Malayan pit viper *Calloselasma rhodostoma*. Comparative sequence analysis and characterization of active and inactive forms of the enzyme. *Eur. J. Biochem.* **268**, 1679–1686 <https://doi.org/10.1046/j.1432-1327.2001.02042.x>
- 73 Sun, M.Z., Guo, C., Tian, Y., Chen, D., Greenaway, F.T. and Liu, S. (2010) Biochemical, functional and structural characterization of akbu-LAAO: a novel snake venom L-amino acid oxidase from *Agkistrodon blomhoffii ussurensis*. *Biochimie* **92**, 343–349 <https://doi.org/10.1016/j.biochi.2010.01.013>
- 74 Ribeiro, P.H., Zuliani, J.P., Fernandes, C.F.C., Calderon, L.A., Stábéli, R.G., Nomizo, A. et al. (2016) Mechanism of the cytotoxic effect of L-amino acid oxidase isolated from *Bothrops alternatus* snake venom. *Int. J. Biol. Macromol.* **92**, 329–337 <https://doi.org/10.1016/j.ijbiomac.2016.07.022>
- 75 Zhang, L. and Wei, L.-J. (2007) ACTX-8, a cytotoxic L-amino acid oxidase isolated from *Agkistrodon acutus* snake venom, induces apoptosis in hela cervical cancer cells. *Life Sci.* **80**, 1189–1197 <https://doi.org/10.1016/j.lfs.2006.12.024>
- 76 Izidoro, L.F.M., Ribeiro, M.C., Souza, G.R.L., Sant'Ana, C.D., Hamaguchi, A., Homsí-Brandeburgo, M.I. et al. (2006) Biochemical and functional characterization of an L-amino acid oxidase isolated from *Bothrops pirajai* snake venom. *Bioorg. Med. Chem.* **14**, 7034–7043 <https://doi.org/10.1016/j.bmc.2006.06.025>
- 77 Singh, M., Sharma, H. and Singh, N. (2007) Hydrogen peroxide induces apoptosis in HeLa cells through mitochondrial pathway. *Mitochondrion* **7**, 367–373 <https://doi.org/10.1016/j.mito.2007.07.003>
- 78 Alves, R.M., Antonucci, G.A., Paiva, H.H., Cintra, A.C.O., Franco, J.J., Mendonça-Franqueiro, E.P. et al. (2008) Evidence of caspase-mediated apoptosis induced by L-amino acid oxidase isolated from *Bothrops atrox* snake venom. *Comp. Biochem. Physiol. A Mol. Integr. Physiol.* **151**, 542–550 <https://doi.org/10.1016/j.cbpa.2008.07.007>
- 79 Burin, S.M., Ayres, L.R., Neves, R.P., Ambrósio, L., de Moraes, F.R., Dias-Baruffi, M. et al. (2013) L-amino acid oxidase isolated from *Bothrops pirajai* induces apoptosis in BCR-ABL-positive cells and potentiates imatinib mesylate effect. *Basic Clin. Pharmacol. Toxicol.* **113**, 103–112 <https://doi.org/10.1111/bcpt.12073>
- 80 Suhr, S.M. and Kim, D.S. (1996) Identification of the snake venom substance that induces apoptosis. *Biochem. Biophys. Res. Commun.* **224**, 134–139 <https://doi.org/10.1006/bbrc.1996.0996>
- 81 Torii, S., Naito, M. and Tsuruo, T. (1997) Apoxin I, a novel apoptosis-inducing factor with L-amino acid oxidase activity purified from Western diamondback rattlesnake venom. *J. Biol. Chem.* **272**, 9539–9542 <https://doi.org/10.1074/jbc.272.14.9539>
- 82 Fung, S.Y., Lee, M.L. and Tan, N.H. (2015) Molecular mechanism of cell death induced by king cobra (*Ophiophagus hannah*) venom L-amino acid oxidase. *Toxicon* **96**, 38–45 <https://doi.org/10.1016/j.toxicon.2015.01.012>
- 83 de Melo Alves Paiva, R., de Freitas Figueiredo, R., Antonucci, G.A., Paiva, H.H., de Lourdes Pires Bianchi, M., Rodrigues, K.C. et al. (2011) Cell cycle arrest evidence, parasiticidal and bactericidal properties induced by L-amino acid oxidase from *Bothrops atrox* snake venom. *Biochimie* **93**, 941–947 <https://doi.org/10.1016/j.biochi.2011.01.009>
- 84 Zhang, L. and Wu, W.T. (2008) Isolation and characterization of ACTX-6: a cytotoxic L-amino acid oxidase from *Agkistrodon acutus* snake venom. *Nat. Prod. Res.* **22**, 554–563 <https://doi.org/10.1080/14786410701592679>
- 85 Ande, S.R., Kommoju, P.R., Draxl, S., Murkovic, M., Macheroux, P., Ghisla, S. et al. (2006) Mechanisms of cell death induction by L-amino acid oxidase, a major component of ophidian venom. *Apoptosis* **11**, 1439–1451 <https://doi.org/10.1007/s10495-006-7959-9>
- 86 Yu, L., Chen, Y. and Tooze, S.A. (2018) Autophagy pathway: cellular and molecular mechanisms. *Autophagy* **14**, 207–215 <https://doi.org/10.1080/15548627.2017.1378838>
- 87 Lee, M.L., Fung, S.Y., Chung, I., Pailoor, J., Cheah, S.H. and Tan, N.H. (2014) King cobra (*Ophiophagus hannah*) venom L-amino acid oxidase induces apoptosis in PC-3 cells and suppresses PC-3 solid tumour growth in a tumour xenograft mouse model. *Int. J. Med. Sci.* **11**, 593–601 <https://doi.org/10.7150/ijms.8096>

- 88 Lu, W., Hu, L., Yang, J., Sun, X., Yan, H., Liu, J. et al. (2018) Isolation and pharmacological characterization of a new cytotoxic L-amino acid oxidase from *Bungarus multicinctus* snake venom. *J. Ethnopharmacol.* **213**, 311–320 <https://doi.org/10.1016/j.jep.2017.11.026>
- 89 Abidin SA, Z., Rajadurai, P., Hoque Chowdhury, M.E., Othman, I. and Naidu, R. (2018) Cytotoxic, anti-proliferative and apoptosis activity of L-amino acid oxidase from Malaysian *Cryptelytrops purpureomaculatus* (CP-LAAO) venom on human colon cancer cells. *Molecules* **23**, E1388 <https://doi.org/10.3390/molecules23061388>
- 90 Calvete, J.J. (2017) Venomics: integrative venom proteomics and beyond. *Biochem J.* **474**, 611–634 <https://doi.org/10.1042/BCJ20160577>
- 91 Warrell, D.A. (2010) Snake bite. *Lancet* **375**, 77–88 [https://doi.org/10.1016/S0140-6736\(09\)61754-2](https://doi.org/10.1016/S0140-6736(09)61754-2)
- 92 Butrón, E., Ghelestam, M. and Gutiérrez, J.M. (1993) Effects on cultured mammalian cells of myotoxin III, a phospholipase A₂ isolated from *Bothrops asper* (terciopelo) venom. *Biochim. Biophys. Acta* **1179**, 253–259 [https://doi.org/10.1016/0167-4889\(93\)90080-9](https://doi.org/10.1016/0167-4889(93)90080-9)
- 93 Cedro, R.C.A., Menaldo, D.L., Costa, T.R., Zoccal, K.F., Sartim, M.A., Santos-Filho, N.A. et al. (2018) Cytotoxic and inflammatory potential of a phospholipase A₂ from *Bothrops jararaca* snake venom. *J. Venom. Anim. Toxins Inc. Trop. Dis.* **24**, 33 <https://doi.org/10.1186/s40409-018-0170-y>
- 94 Bezerra, P.H.A., Ferreira, I.M., Franceschi, B.T., Bianchini, F., Ambrósio, L., Cintra, A.C.O. et al. (2019) BthTX-I from *Bothrops jararacussu* induces apoptosis in human breast cancer cell lines and decreases cancer stem cell subpopulation. *J. Venom. Anim. Toxins Inc. Trop. Dis.* **25**, e20190010 <https://doi.org/10.1590/1678-9199-jvatitd-2019-0010>
- 95 Chioato, L., Aragão, E.A., Ferreira T, L., Medeiros, A.I., Faccioli, L.H. and Ward, R.J. (2007) Mapping of the structural determinants of artificial and biological membrane damaging activities of a Lys49 phospholipase A₂ by scanning alanine mutagenesis. *Biochim. Biophys Acta* **1768**, 1247–1257 <https://doi.org/10.1016/j.bbamem.2007.01.023>
- 96 Stábéli, R.G., Amui, S.F., Sant'Ana, C.D., Pires, M.G., Nomizo, A., Monteiro, M.C. et al. (2006) *Bothrops moojeni* myotoxin-II, a Lys49-phospholipase A₂ homologue: an example of function versatility of snake venom proteins. *Comp. Biochem. Physiol. C Toxicol. Pharmacol.* **142**, 371–381 <https://doi.org/10.1016/j.cbpc.2005.11.020>
- 97 Corin, R.E., Viskatis, L.J., Vidal, J.C. and Etcheverry, M.A. (1993) Cytotoxicity of crotoxin on murine erythroleukemia cells in vitro. *Invest New Drugs.* **11**, 11–15 <https://doi.org/10.1007/BF00873905>
- 98 Rudd, C.J., Viskatis, L.J., Vidal, J.C. and Etcheverry, M.A. (1994) In vitro comparison of cytotoxic effects of crotoxin against three human tumours and a normal human epidermal keratinocyte cell line. *Invest. New Drugs.* **12**, 183–184 <https://doi.org/10.1007/BF00873958>
- 99 Muller, S.P., Silva, V.A.O., Silvestrini, A.V.P., de Macedo, L.H., Caetano, G.F., Reis, R.M. et al. (2018) Crotoxin from *Crotalus durissus terrificus* venom: In vitro cytotoxic activity of a heterodimeric phospholipase A₂ on human cancer-derived cell lines. *Toxicon* **156**, 13–22 <https://doi.org/10.1016/j.toxicon.2018.10.306>
- 100 Casais E Silva, L.L., Teixeira, C.F.P., Lebrun, I., Lomonte, B., Alape-Girón, A. and Gutiérrez, J.M. (2016) Lemnitoxin, the major component of *Micrurus lemniscatus* coral snake venom, is a myotoxic and pro-inflammatory phospholipase A₂. *Toxicol Lett.* **257**, 60–71 <https://doi.org/10.1016/j.toxlet.2016.06.005>
- 101 Chen, K.C., Kao, P.H., Lin, S.R. and Chang, L.S. (2009) Upregulation of Fas and FasL in Taiwan cobra phospholipase A₂ treated human neuroblastoma SK-N-SH cells through ROS- and Ca²⁺-mediated p38 MAPK activation. *J. Cell. Biochem.* **106**, 93–102 <https://doi.org/10.1002/jcb.21979>
- 102 Rudrammaji, L.M. and Gowda, T.V. (1998) Purification and characterization of three acidic, cytotoxic phospholipases A₂ from Indian cobra (*Naja naja*) venom. *Toxicon* **36**, 921–932 [https://doi.org/10.1016/S0041-0101\(97\)00097-4](https://doi.org/10.1016/S0041-0101(97)00097-4)
- 103 Dutta, S., Sinha, A., Dasgupta, S. and Mukherjee, A.K. (2019) Binding of a *Naja naja* venom acidic phospholipase A₂ cognate complex to membrane-bound vimentin of rat L6 cells: Implications in cobra venom-induced cytotoxicity. *Biochim. Biophys. Acta Biomembr.* **1861**, 958–977 <https://doi.org/10.1016/j.bbamem.2019.02.002>
- 104 Chwetzoff, S., Tsunashawa, S., Sakiyama, F. and Ménez, A. (1989) Nigexine, a phospholipase A₂ from cobra venom with cytotoxic properties not related to esterase activity. Purification, amino acid sequence, and biological properties. *J. Biol. Chem.* **264**, 13289–13297 PMID: 2753914
- 105 Liu, J.W., Chai, M.Q., Du, X.Y., Song, J.G. and Zhou, Y.C. Purification and characterization of L-amino acid oxidase from *Agkistrodon halys pallas* venom. *Acta Biochim. Biophys. Sin.* **34**, 305–310 PMID: 12019442
- 106 Braga, M.D.M., Martins, A.M.C., Amora, D.N., de Menezes, D.B., Toyama, M.H., Toyama, D.O. et al. (2008) Purification and biological effects of L-amino acid oxidase isolated from *Bothrops insularis* venom. *Toxicon* **51**, 199–207 <https://doi.org/10.1016/j.toxicon.2007.09.003>
- 107 de Vieira Santos, M.M., Sant'Ana, C.D., Giglio, J.R., da Silva, R.J., Sampaio, S.V., Soares, A.M. et al. (2008) Antitumoural effect of an L-amino acid oxidase isolated from *Bothrops jararaca* snake venom. *Basic Clin. Pharmacol. Toxicol.* **102**, 533–542 <https://doi.org/10.1111/j.1742-7843.2008.00229.x>
- 108 Bregge-Silva, C., Nonato, M.C., de Albuquerque, S., Ho, P.L., de Azevedo ILM, J., Diniz MR, V. et al. (2012) Isolation and biochemical, functional and structural characterization of a novel L-amino acid oxidase from *Lachesis muta* snake venom. *Toxicon* **60**, 1263–1276 <https://doi.org/10.1016/j.toxicon.2012.08.008>
- 109 Ahn, M.Y., Lee, B.M. and Kim, Y.S. (1997) Characterization and cytotoxicity of L-amino acid oxidase from the venom of king cobra (*Ophiophagus hannah*). *Int. J. Biochem. Cell Biol.* **29**, 911–919 [https://doi.org/10.1016/S1357-2725\(97\)00024-1](https://doi.org/10.1016/S1357-2725(97)00024-1)
- 110 Lee, M.L., Chung, I., Fung, S.Y., Kanthimathi, M.S. and Tan, N.H. (2014) Antiproliferative activity of king cobra (*Ophiophagus hannah*) venom L-amino acid oxidase. *Basic Clin. Pharmacol. Toxicol.* **114**, 336–343 <https://doi.org/10.1111/bcpt.12155>
- 111 Sun, L.-K., Yoshii, Y., Hyodo, A., Tsurushima, H., Saito, A., Harakuni, T. et al. (2003) Apoptotic effect in the glioma cells induced by specific protein extracted from Okinawa Habu (*Trimeresurus flavoviridis*) venom in relation to oxidative stress. *Toxicol In Vitro* **17**, 169–177 [https://doi.org/10.1016/S0887-2333\(03\)00010-9](https://doi.org/10.1016/S0887-2333(03)00010-9)
- 112 Zhang, Y.J., Wang, J.H., Lee, W.H., Wang, Q., Liu, H., Zheng, Y.T. et al. (2003) Molecular characterization of *Trimeresurus stejnegeri* venom L-amino acid oxidase with potential anti-HIV activity. *Biochem. Biophys. Res. Commun.* **309**, 598–604 <https://doi.org/10.1016/j.bbrc.2003.08.044>